Abstract:Background: Hepatic inflammatory and fibrotic lesions promote the development of cirrhosir and hepatocellular carcinoma in patients with chronic Hepatitis 8 (CHB). Farly recognition of hepatic histopathological changes and timely initiation of antivical therapy can delay or even reverse disease progression. Objectives: This study aimed to analyze non invasive diagnostic indicators associated inch different inflammation grades, fibrosis stages, and Hepatios degrees in CHB patients, and their outcomes after antiviral therapy Methods: A total of si CHB patients treated at the Third People's Hospital of Shenzhen from January December 2019 were selected for inflammation grading (G) and fibrous staging (5) based on liver puncture examination results. The patients were further dirnded into mild, moderate, and severe chronic Hepatitis groups. Correlation analysis was conducted via Spearman. The diagnostic performance of the relevant indexes for inflammation grading, bibrosi staging, and Hepatios degree grading was evaluated using receiver operator characteristics (ROC) The performance of different ROC curves was further compared using the DeLong rest. The effects of of antiviral drugs on patients with different liver hutopathological degrees were comparatively analyzed after 24, 48, 72, and 95 weeks. Results: Data analysis at baseline showed that 86.81% (79 of 91) of all patients were male. Additionally, about 61.54% (16 of 26), 30.77% (8 of 26), 85.19% (23 of 27), and 62.96% (17 of 27) of patients with normal ALT had G >= 2, G >= 3, S >= 2, and S >= 3, respectively inflammation grade, fibrosis stage, and Hepatitis degree were positively correlated with portal vein internal diameter, spleen thickness. LN, GPR, FIB-4, and 5 index, and negatively correlated with PLT (P<0.05). The area under the curve (AUC) of the ROC assessed multifactorial combinations PSUPTL, PSWPAHPCL, and PSWPHCL for predicting the risk of developing G3 inflammation, 5:3 fibrosis, and moderate to severe Hepatitis in patients with CHB were 0.806, 0.843, and 0.778, respectively. The diagnostic accuracies were higher than some of these factors applied indindually and some commonly used serological markers. HBV DNA levels were significantly lower in different Hepatitis groups after 24 werks of antiviral therapy than before treatment (P<0.05). Furthermore, the ALT normalization rate and HBV DNA clearance rate were slightly higher in the moderate and severe groups than in the mild group alter 48 werks of treatment (P>0.05). The serum liepatitis B envelope antigen (HBeAg) level was nguficantly lower in the severe group than in the mild group after 72 weeks of antiviral therapy (H7.043, P=0.030). Although only the HBeAg serologic conversion rate was significantly different at 96 weeks among the three groups (chi(2) = 12389,P=0.002), (BeAg negative and the serologic conversion rates higher in the severe group at each time point than in the mild and moderate groups Conclusions: Multiple non invasive indicators are strongly associated with different degrees of liver histopathology in patients with chronic HBV infection. Therefore, PSBPTL, PSWPAHPCI, and PSWPHCL can be used to predict the risk of developing Gas inflammation, 53 fibrosis, and moderate to severe Hepatitis in these pacients, respectively. Moreover, short term anuviral therapy has a more pronounced effect on patients with severe Hepatitis by improving hepatic inflammation and inhibiting viral replication.

Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Development and Validation of a Non-Invasive Model for Predicting Liver Cirrhosis in Patients with Chronic Hepatitis B

A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels

Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters.

Establishment and Validation of a Simple Noninvasive Model to Predict Significant Liver Fibrosis in Patients with Chronic Hepatitis B

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

Prediction of Significant Fibrosis in HBeAg-positive Patients with Chronic Hepatitis B by a Noninvasive Model

A novel index using routinely clinical parameters for predicting significant liver inflammation in chronic hepatitis B.

Predictive Model for Inflammation Grades of Chronic Hepatitis B: Large-scale Analysis of Clinical Parameters and Gene Expressions

Development of a Machine Learning-Based Model to Predict Hepatic Inflammation in Chronic Hepatitis B Patients with Concurrent Hepatic Steatosis: a Cohort Study

A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B.

Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase

A Novel Non-Invasive Model for the Prediction of Advanced Liver Fibrosis in Chronic Hepatitis B Patients with NAFLD.

The Prediction and Validation of Liver Fibrosis by a Noninvasive Model and Validation in Patients with Chronic Hepatitis B

Non-invasive Diagnostic Indicators and Antiviral Treatment Efficacy in CHB Patients with Different Liver Histopathological Degrees

A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease

Predictive Performances of Blood Parameter Ratios for Liver Inflammation and Advanced Liver Fibrosis in Chronic Hepatitis B Infection

Development and Validation of a Nomogram to Predict Significant Liver Inflammation in Patients with Chronic Hepatitis B

Selected Cytokines Serve As Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients with Normal to Mildly Elevated Aminotransferases.